Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
Status:
Unknown status
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
- The purpose of this study is to determine the level of inhibition of platelet activation
of an approved thienopyridine(clopidogrel or prasugrel) and aspirin regimen in the
setting of drug eluting coronary stent implantation.
- In subjects with high residual levels of platelet reactivity after receiving either a
maintenance or loading dose of either clopidogrel or prasugrel, a cross over of
thienopyridine treatment to the alternate medication will occur.
- The study tests the hypothesis that adequate platelet inhibition will occur in subjects
who have high levels of platelet reactivity and are subsequently switched from
clopidogrel to prasugrel(loading or maintenance dose) without increased episodes of
bleeding or MACE events at discharge and 30 days post Percutaneous Coronary Intervention
(PCI).